These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2. Harrison LM; Gaines DW; Babu US; Balan KV; Reimschuessel R; Do AB; Pereira MR; Bigley EC; Ferguson M; Mehta A; Williams KM Microb Pathog; 2018 Oct; 123():250-258. PubMed ID: 30016681 [TBL] [Abstract][Full Text] [Related]
6. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Sauter KA; Melton-Celsa AR; Larkin K; Troxell ML; O'Brien AD; Magun BE Infect Immun; 2008 Oct; 76(10):4469-78. PubMed ID: 18694970 [TBL] [Abstract][Full Text] [Related]
7. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Palermo M; Alves-Rosa F; Rubel C; Fernández GC; Fernández-Alonso G; Alberto F; Rivas M; Isturiz M Clin Exp Immunol; 2000 Jan; 119(1):77-83. PubMed ID: 10606967 [TBL] [Abstract][Full Text] [Related]
8. Development of a Mouse Model of Shiga Toxin 2 (Stx2) Intoxication for Testing Therapeutic Agents Against Hemolytic Uremic Syndrome (HUS). Mejias MP; Fernandez-Brando RJ; Ramos MV; Abrey-Recalde MJ; Zotta E; Meiss R; Palermo MS Curr Pharm Des; 2016; 22(34):5294-5299. PubMed ID: 27356777 [TBL] [Abstract][Full Text] [Related]
9. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235 [TBL] [Abstract][Full Text] [Related]
10. LPS-primed CD11b Niu S; Paluszynski J; Bian Z; Shi L; Kidder K; Liu Y Sci Rep; 2018 Mar; 8(1):3994. PubMed ID: 29507316 [TBL] [Abstract][Full Text] [Related]
11. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697 [TBL] [Abstract][Full Text] [Related]
12. The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome. Gomez SA; Abrey-Recalde MJ; Panek CA; Ferrarotti NF; Repetto MG; Mejías MP; Fernández GC; Vanzulli S; Isturiz MA; Palermo MS Clin Exp Immunol; 2013 Sep; 173(3):463-72. PubMed ID: 23607458 [TBL] [Abstract][Full Text] [Related]
13. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Dran GI; Fernández GC; Rubel CJ; Bermejo E; Gomez S; Meiss R; Isturiz MA; Palermo MS Kidney Int; 2002 Oct; 62(4):1338-48. PubMed ID: 12234304 [TBL] [Abstract][Full Text] [Related]
14. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. Keepers TR; Psotka MA; Gross LK; Obrig TG J Am Soc Nephrol; 2006 Dec; 17(12):3404-14. PubMed ID: 17082244 [TBL] [Abstract][Full Text] [Related]
15. Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome. He X; Quiñones B; Loo MT; Loos S; Scavia G; Brigotti M; Levtchenko E; Monnens L Acta Paediatr; 2015 Dec; 104(12):e564-8. PubMed ID: 26361237 [TBL] [Abstract][Full Text] [Related]
16. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Siegler RL; Obrig TG; Pysher TJ; Tesh VL; Denkers ND; Taylor FB Pediatr Nephrol; 2003 Feb; 18(2):92-6. PubMed ID: 12579394 [TBL] [Abstract][Full Text] [Related]
17. Leukotriene C4 increases the susceptibility of adult mice to Shiga toxin-producing Escherichia coli infection. Cabrera G; Fernández-Brando RJ; Mejías MP; Ramos MV; Abrey-Recalde MJ; Vanzulli S; Vermeulen M; Palermo MS Int J Med Microbiol; 2015 Dec; 305(8):910-7. PubMed ID: 26456732 [TBL] [Abstract][Full Text] [Related]
18. Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains. Brando RJ; Miliwebsky E; Bentancor L; Deza N; Baschkier A; Ramos MV; Fernández GC; Meiss R; Rivas M; Palermo MS Clin Exp Immunol; 2008 Aug; 153(2):297-306. PubMed ID: 18549440 [TBL] [Abstract][Full Text] [Related]
20. A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo. Li T; Tu W; Liu Y; Zhou P; Cai K; Li Z; Liu X; Ning N; Huang J; Wang S; Huang J; Wang H Sci Rep; 2016 Feb; 6():21837. PubMed ID: 26903273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]